Cambridge researchers have found the strongest evidence to date that human pluripotent stem cells – cells that can give rise to all tissues of the body – will develop normally once transplanted into an embryo. ̽»¨Ö±²¥findings, published today in the journal Cell Stem Cell, could have important implications for regenerative medicine.
A collaboration between the ̽»¨Ö±²¥ of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known human enzyme, which may have implications for treating respiratory diseases such as asthma.
GSK, the ̽»¨Ö±²¥ of Cambridge and Cambridge ̽»¨Ö±²¥ Hospitals NHS Foundation Trust today announce their Strategic Partnership, with the long-term ambition to jointly deliver new medicine to patients in the next 5-10 years.
Almost one in four of the world’s cases of tuberculosis (TB) are in India and the disease is constantly adapting itself to outwit our medicines. Could the answer lie in targeting not the bacteria but its host, the patient?
Nerve cells damaged in diseases such as multiple sclerosis (MS), ‘talk’ to stem cells in the same way that they communicate with other nerve cells, calling out for ‘first aid’, according to new research from the ̽»¨Ö±²¥ of Cambridge.
Patients with the most dangerous type of high blood pressure will be able to receive far more effective treatment after Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Technology assisting people with type 1 diabetes edges closer to perfection.
A ‘brain training’ iPad game developed and tested by researchers at the ̽»¨Ö±²¥ of Cambridge may improve the memory of patients with schizophrenia, helping them in their daily lives at work and living independently, according to research published today.
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
Cambridge has been part of a successful £16 million bid to work with the MRC, GSK and four other UK universities in a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients.
© 2025 ̽»¨Ö±²¥ of Cambridge